LogoTLDR Biotech
Frequently Asked Questions (FAQ)
Media Partners
TLDR Biotech Deep Dives
TLDR Biotech Deep Dives

Long Form Content

Login
Subscribe

Long Form Content

Longer Form TLDR Biotech content that isn't the usual daily newsletter.

Long Form Content

The $4 Million Problem [Guest Post]

Dec 13, 2025

•

14 min read

The $4 Million Problem [Guest Post]

How a $25M startup is solving gene therapy's $4 million payment problem

Anis Fahandej-Sadi
Anis Fahandej-Sadi

Long Form Content

Building Scalable Biotech Industry Networks - The Biokeiretsu

Nov 29, 2025

•

12 min read

Building Scalable Biotech Industry Networks - The Biokeiretsu

Biotechnologies Are the Petrochemicals of the Electric Tech Stack

Anis Fahandej-Sadi
Anis Fahandej-Sadi

Long Form Content

Why Biotech is Mortgaging Its Future

Nov 22, 2025

•

12 min read

Why Biotech is Mortgaging Its Future

Inside the $3.5 Billion Biotech Royalty Financing Surge

Anis Fahandej-Sadi
Anis Fahandej-Sadi

Long Form Content

Beyond the Hype Cycle: Breakout Ventures' Nima Ronaghi on What Actually Drives Biotech Value

Sep 20, 2025

•

14 min read

Beyond the Hype Cycle: Breakout Ventures' Nima Ronaghi on What Actually Drives Biotech Value

Hot takes on value creation in biotech

Anis Fahandej-Sadi
Anis Fahandej-Sadi

Long Form Content

TLDR Biotech Big Three Saturday: American Biotech in Flux

Aug 30, 2025

•

9 min read

TLDR Biotech Big Three Saturday: American Biotech in Flux

Public health dismantling, Chinese asset deals continue, and domestic manufacturing only goes so far

Anis Fahandej-Sadi
Anis Fahandej-Sadi

Long Form Content

Moloch and Medicine: Why Good Intentions Built a Broken System, and Why CGT Might Fix It All (Sort Of)

Aug 23, 2025

•

21 min read

Moloch and Medicine: Why Good Intentions Built a Broken System, and Why CGT Might Fix It All (Sort Of)

Hot takes on current incentive structures

Anis Fahandej-Sadi
Anis Fahandej-Sadi

Long Form Content

The Biotech Funding Crisis: How Broken Models and Regulatory Chaos Are Reshaping an Industry

Aug 16, 2025

•

16 min read

The Biotech Funding Crisis: How Broken Models and Regulatory Chaos Are Reshaping an Industry

The biotech funding model needs a major overhaul

Anis Fahandej-Sadi
Anis Fahandej-Sadi

Long Form Content

Lowering CAR-T Costs: Paths to more affordable cell therapies

Jun 18, 2025

•

12 min read

Lowering CAR-T Costs: Paths to more affordable cell therapies

A long form piece by yours truly - originally published on Signals

Anis Fahandej-Sadi
Anis Fahandej-Sadi
TLDR Biotech

TLDR Biotech

Daily coverage of the biotech and pharma industry, straight to your inbox and all in one skimmable email.

I consent to receive newsletters via email. Terms of use and Privacy policy.


Home

FAQ

Media Partners

© 2026 TLDR Biotech.
Report abusePrivacy policyTerms of use
beehiivPowered by beehiiv